{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "22951311",
  "DateCompleted": {
    "Year": "2013",
    "Month": "05",
    "Day": "01"
  },
  "DateRevised": {
    "Year": "2012",
    "Month": "12",
    "Day": "03"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2012",
        "Month": "08",
        "Day": "19"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.virusres.2012.08.007",
      "S0168-1702(12)00303-6"
    ],
    "Journal": {
      "ISSN": "1872-7492",
      "JournalIssue": {
        "Volume": "170",
        "Issue": "1-2",
        "PubDate": {
          "Year": "2012",
          "Month": "Dec"
        }
      },
      "Title": "Virus research",
      "ISOAbbreviation": "Virus Res"
    },
    "ArticleTitle": "A prime/boost strategy by DNA/fowlpox recombinants expressing a mutant E7 protein for the immunotherapy of HPV-associated cancers.",
    "Pagination": {
      "StartPage": "44",
      "EndPage": "52",
      "MedlinePgn": "44-52"
    },
    "Abstract": {
      "AbstractText": [
        "Development of effective therapeutic vaccines against human papilloma virus (HPV) infections remains a priority, considering the high number of new cases of cervical cancer each year by high-risk HPVs, in particular by HPV-16. Vaccines expressing the E7 oncoprotein, which is detectable in all HPV-positive pre-cancerous and cancer cells, might clear already established tumors and support the treatment of HPV-related lesions. In this study, DNA or fowlpox virus recombinants expressing the harmless variant E7GGG of the HPV-16 E7 oncoprotein (DNA(E7GGG) and FP(E7GGG)) were generated. Two immunization regimens were tested in a pre-clinical mouse model by homologous (FP/FP) or heterologous (DNA/FP) prime-boost protocols to evaluate the immune response and therapeutic efficacy of the proposed HPV-16 vaccine. Low levels of anti-E7-specific antibodies were elicited after immunization, and in vivo experiments resulted in a higher number of tumor-free mice after the heterologous immunization. These results establish a preliminary indication for therapy of HPV-related tumors by the combined use of DNA and avipox recombinants, which might represent safer immunogens than vaccinia-based vaccines."
      ],
      "CopyrightInformation": "Copyright \u00a9 2012 Elsevier B.V. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Pharmacological Sciences, Universit\u00e0 di Milano, Milan, Italy. antonia.radaelli@unimi.it"
          }
        ],
        "LastName": "Radaelli",
        "ForeName": "Antonia",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "De Giuli Morghen",
        "ForeName": "Carlo",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Zanotto",
        "ForeName": "Carlo",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Pacchioni",
        "ForeName": "Sole",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Bissa",
        "ForeName": "Massimiliano",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Franconi",
        "ForeName": "Rosella",
        "Initials": "R"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Massa",
        "ForeName": "Silvia",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Paolini",
        "ForeName": "Francesca",
        "Initials": "F"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Muller",
        "ForeName": "Antonio",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Venuti",
        "ForeName": "Aldo",
        "Initials": "A"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Netherlands",
    "MedlineTA": "Virus Res",
    "NlmUniqueID": "8410979",
    "ISSNLinking": "0168-1702"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Cancer Vaccines"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Mutant Proteins"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Papillomavirus E7 Proteins"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Papillomavirus Vaccines"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Vaccines, DNA"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "genetics",
        "immunology",
        "therapeutic use"
      ],
      "DescriptorName": "Cancer Vaccines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Cell Line"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Fowlpox virus"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Gene Expression"
    },
    {
      "QualifierName": [
        "genetics",
        "immunology"
      ],
      "DescriptorName": "Human papillomavirus 16"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Immunity, Cellular"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Immunity, Humoral"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Immunization Schedule"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Immunotherapy"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Mice"
    },
    {
      "QualifierName": [
        "immunology"
      ],
      "DescriptorName": "Mutant Proteins"
    },
    {
      "QualifierName": [
        "immunology",
        "therapy",
        "virology"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [
        "genetics",
        "immunology"
      ],
      "DescriptorName": "Papillomavirus E7 Proteins"
    },
    {
      "QualifierName": [
        "genetics",
        "therapeutic use"
      ],
      "DescriptorName": "Papillomavirus Vaccines"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Plasmids"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Transgenes"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Vaccines, DNA"
    }
  ]
}